Could a Tiny Electrical Charge Help Regrow Cartilage? This UConn Technology Is Headed for Veterinary Medicine

PetVivo Holdings has acquired a UConn startup developing biodegradable materials that generate electricity from movement—and researchers believe the technology could eventually offer a new way to treat osteoarthritis in dogs and horses.

For a dog struggling to get up after a nap or a horse becoming increasingly stiff under saddle, osteoarthritis can slowly transform ordinary movement into something painful. Veterinarians have an expanding collection of options for managing that pain, but repairing the cartilage damaged by osteoarthritis remains a much more difficult problem.

A technology developed at the University of Connecticut is approaching the problem from a completely different direction. Instead of delivering another drug into an arthritic joint, researchers are investigating whether the mechanical forces generated by the animal's own movement can be converted into tiny electrical signals that encourage the body to regenerate cartilage.

Now that technology is moving closer to the animal health marketplace.

PetVivo Holdings, a veterinary biotechnology and biomedical device company focused in part on osteoarthritis in dogs and horses, has acquired PiezoBioMembrane, a startup founded in 2021 by UConn mechanical engineering professor Thanh Nguyen. The acquisition brings together PetVivo's animal health commercialization experience with a biomaterials platform that sounds almost futuristic: soft, biodegradable materials capable of generating electricity when they're squeezed, stretched, or otherwise subjected to mechanical force.

The long-term possibilities extend well beyond arthritis—and even beyond veterinary medicine—but osteoarthritis may be one of the technology's most intriguing applications.

Turning Movement Into Medicine

At the center of Nguyen's research are piezoelectric materials, which have the unusual ability to convert mechanical energy into electrical energy. Apply force to the material and it generates an electrical charge.

Piezoelectricity itself isn't new. The challenge has been making it useful inside the body. Traditional piezoelectric materials are often ceramic, which means they're hard and brittle—not exactly ideal characteristics for something intended to interact with soft biological tissue.

Nguyen's laboratory developed a different approach, creating piezoelectric materials that are soft, flexible, and biodegradable. Rather than remaining permanently inside the patient, the materials are designed to gradually break down and disappear after they've done their job.

For osteoarthritis, the concept is particularly clever because joints already experience mechanical forces every time an animal moves.

The material could be implanted or injected directly into an affected joint without requiring drugs, cells, or other active pharmaceutical ingredients. Once there, ordinary movement places mechanical force on the material. That force generates a small electrical charge, which researchers believe can stimulate cartilage regeneration.

In essence, walking becomes part of the treatment.

“The body can be electrically stimulated to regrow,” Nguyen explained. He compares the biomaterial to “an everlasting battery” that works whenever force is applied and then eventually disappears safely inside the body.

Why Electricity Might Matter to a Joint

The idea of using electricity to influence healing may sound unusual, but electrical activity is already part of normal biology. Cells respond to electrical and mechanical signals, and those signals can influence processes involved in tissue growth and repair.

Nguyen's technology attempts to take advantage of those natural mechanisms without requiring an implanted electronic device, external power supply, or conventional battery. The material itself generates the electrical stimulation in response to movement.

That could be especially interesting in osteoarthritis, where loss and deterioration of articular cartilage contribute to pain and declining joint function. Many existing therapies are designed primarily to control pain and inflammation or improve joint function. A technology capable of meaningfully encouraging cartilage regeneration would represent a fundamentally different therapeutic strategy.

There is, of course, an important distinction between a promising regenerative technology and a clinically proven treatment. The acquisition does not mean veterinarians will suddenly be injecting piezoelectric material into arthritic Labradors next week. The technology still has to move through product development, regulatory evaluation, and appropriate clinical studies before its safety and effectiveness can be established for specific veterinary indications.

But PetVivo clearly sees enough potential to invest in taking that next step.

From a University Lab to Dogs and Horses

PetVivo CEO John Lai described PiezoBioMembrane as more than a single osteoarthritis technology. He sees the acquisition as a way to build a broader functional biomaterials platform that could eventually produce multiple veterinary and human medical products.

“PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets,” Lai said in announcing the acquisition.

The strategy is to combine the scientific work coming out of Nguyen's laboratory with PetVivo's experience in product development, commercialization, regulation, and animal health. That's a crucial transition for university research. A discovery can perform beautifully in a laboratory and still be years away from becoming something a veterinarian can actually use.

Nguyen is very aware of that gap. His research philosophy has been to demonstrate that a technology works in laboratory and animal models and then find a path toward commercialization through a startup, licensing agreement, or industry partnership.

The PetVivo acquisition is one of those paths.

Veterinary Medicine Could Be the Beginning, Not the End

There's also an interesting One Health angle to the deal. PetVivo is an animal health company, but Nguyen sees veterinary medicine as part of a much larger trajectory for his technology.

“PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use,” Nguyen said.

That possibility makes naturally occurring osteoarthritis in dogs and horses particularly interesting. Companion animals develop many diseases that closely resemble conditions seen in humans, and studying therapies in veterinary patients can sometimes generate knowledge relevant to both species.

Nguyen's biomaterials research already crosses those boundaries. His laboratory has explored applications involving wound healing, tissue regeneration, implanted force sensors, cartilage and bone regeneration, drug delivery, and biodegradable ultrasound technology intended to improve delivery of treatments for tumors.

The underlying idea is the same: design materials that interact with the body, perform a useful function, and then disappear when they're no longer needed.

This Technology Started Somewhere Unexpected

PiezoBioMembrane's origins also show just how far a technology can travel from its first intended application.

Nguyen founded the company during the COVID-19 pandemic after recognizing that his piezoelectric material could potentially be incorporated into a biodegradable face mask. The mechanical force created as a person breathed through the mask generated an electrical charge, providing an additional barrier against viruses.

From a face mask, the technology expanded into regenerative medicine, sensors, drug delivery, and now potentially veterinary orthopedics.

Nguyen has followed a similar commercialization path with another startup, Single-Time Microneedles, which is developing adhesive microneedle patches designed to make vaccines easier to store and deliver. That venture is also in the acquisition process.

His broader research program has attracted substantial federal support, including five R01 grants from the National Institutes of Health for work spanning cartilage and bone regeneration, HIV antibody delivery, and biodegradable ultrasound technology designed to improve chemotherapy delivery for brain cancer.

What This Could Mean for Veterinary Osteoarthritis

Osteoarthritis is one of the most common chronic conditions veterinarians manage in aging companion animals, and the veterinary industry has invested heavily in finding better ways to control it. The emergence of regenerative biomaterials adds another potentially important direction to that work.

The appeal of the PiezoBioMembrane approach is that it isn't simply another formulation intended to temporarily suppress a symptom. Its goal is to use the mechanical environment already present inside a joint to generate a biological signal associated with tissue repair.

A dog walks. A horse moves. The joint applies pressure. The material responds by generating electricity. Eventually, the material biodegrades.

It's an elegant concept.

Whether that elegance translates into meaningful clinical improvement in dogs and horses will ultimately depend on the evidence produced as the technology moves forward. Veterinarians will need data demonstrating safety, durability of response, appropriate patient selection, and meaningful improvements in outcomes before a new biomaterial earns a place alongside established osteoarthritis therapies.

But the acquisition itself is worth watching because it represents something increasingly common in animal health: technologies developed at the intersection of engineering, human medicine, and materials science finding their way into veterinary patients.

For an arthritic dog or horse, the next generation of treatment may not necessarily look like another pill, injection, or conventional implant.

It might be a tiny piece of biodegradable material that turns the animal's own movement into electricity—and asks the body to do something extraordinary with it.

Source: University of Connecticut reporting on the acquisition of PiezoBioMembrane by PetVivo Holdings, with statements from UConn professor and PiezoBioMembrane founder Thanh Nguyen and PetVivo Holdings CEO John Lai.